Cost-Effectiveness of Atomoxetine for Treating Children with ADHD

 ADHD in the News 2018-02-22

The investigators of a study published in Current Medical Research and Opinion compared annual healthcare costs among children prescribed either atomoxetine or extended-release guanfacine, 2 non-stimulants that have been used to treat attention-deficit/hyperactivity disorder. The findings suggested that patients who initiated atomoxetine monotherapy incurred lower all-cause healthcare costs in a single year by $3086, on average.